REFERENCES
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogenes. Science 1987;234:177–182.
- Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart S, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin O. 2002;20(3): 719.
- Romand EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Vissher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Momounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N, Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N England J Med 2005;353(16):1673.
- Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer(GC). J Clin Oncol 2009;27:18s, (suppl;abstr LBA 4509).
- Ramanthan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, CheHX, Finkelstein S. Low expression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan therapy. A phase II trial. Cancer Invest 2004;22(6):858–865.
- Kavanagh DO, Chambers G, O'Grady L, Barry KM, Waldron RP, Bennani F, Eustace PW, Tobbia I. Is Overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 2009;9:1 doi:10.1186/1471-2407-9-1.
- Zhou C, Wu Y-L, Chen G, Feng J, Liu X, Wang C, Zhang S, Wang J, Zhou S, Ren S. Efficacy results from the randomized phase III optimal (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR avtivating mutations. Ann Oncol 2010;21 (suppl; abstr LBA 13).
- Miller DV, Dueck AC, Tenner KS, Jenkins RB, Kaufman PA, Davidson NE, Dakhil SR, Martino S, Roy V, Perez EA. Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. J Clin Oncol 2009;27:15s, (suppl; abstr 520).